SCHEMBL5469767

SCHEMBL5469767

COCC(=NOCc1ccccc1)c1ccc2c(c1)OCO2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.47
RAB9A P51151 5/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
ALDH1A1 P00352 2/20 0.47
MAOB P27338 2/20 0.47
HPGD P15428 1/20 0.46
TAS1R3 Q7RTX0 1/20 0.45
TAS1R1 Q7RTX1 1/20 0.45
CTNNB1 P35222 1/20 0.43
WNT3A P56704 1/20 0.43
TP53 P04637 1/20 0.43
MAPT P10636 1/20 0.43
TSHR P16473 1/20 0.43
ATM Q13315 1/20 0.43
KMT2A Q03164 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 1/20 0.42
MAOA P21397 1/20 0.42
LMNA P02545 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5469763 1.00 NPC1 (0.47) NPC1RAB9ASMN1; SMN2ALDH1A1MAOB
SCHEMBL5457522 0.86 RAB9A (0.47) NPC1RAB9ASMN1; SMN2ALDH1A1MAOB
SCHEMBL5457525 0.86 RAB9A (0.47) NPC1RAB9ASMN1; SMN2ALDH1A1MAOB
SCHEMBL5460785 0.82 MAOB (0.46) NPC1RAB9ASMN1; SMN2ALDH1A1MAOB
SCHEMBL5460781 0.82 MAOB (0.46) NPC1RAB9ASMN1; SMN2ALDH1A1MAOB
SCHEMBL2394692 0.80 MAOB (0.52) NPC1RAB9ASMN1; SMN2ALDH1A1MAOB
SCHEMBL2394690 0.80 MAOB (0.52) NPC1RAB9ASMN1; SMN2ALDH1A1MAOB
SCHEMBL2395645 0.78 NPC1 (0.50) NPC1RAB9ASMN1; SMN2ALDH1A1MAOB
SCHEMBL2395648 0.78 NPC1 (0.50) NPC1RAB9ASMN1; SMN2ALDH1A1MAOB
SCHEMBL5469823 0.78 NPC1 (0.43) NPC1RAB9ASMN1; SMN2ALDH1A1MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8420679-B2 Aminothiazole derivatives and their use as CRF receptor ligands SANOFI (FR) 2013-04-16 US disclosed
US-20070281919-A1 Aminothiazole Derivatives And Their Use As CRF Receptor Ligands SANOFI-AVENTIS (FR) 2007-12-06 US disclosed
EP-1200419-B1 AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS SANOFI SYNTHELABO (FR) 2004-04-14 EP disclosed
EP-1200419-A1 AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS SANOFI-SYNTHELABO (FR) 2002-05-02 EP disclosed
WO-2001005776-A1 AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS SANOFI-SYNTHELABO (FR) 2001-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281919-A1 Aminothiazole Derivatives And Their Use As CRF Receptor Ligands CRH, CRHR1, CRHR2 NPC1 2994/4885RAB9A 3096/4885SMN1; SMN2 4326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.